Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2010-06-25

Clinical Trial Update: Abilify in Bipolar Disorder for 6 Weeks Treatment Effectiveness [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update assessing the 6-week effectiveness of Abilify (aripiprazole) for bipolar disorder. The study, conducted by Korea Otsuka Pharmaceut…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Abilify (aripiprazole)

Snippet

Sponsor: Korea Otsuka Pharmaceutical Co., Ltd. | Conditions: Bipolar Disorder | Phase 4 | Status: COMPLETED